Atypical ischemic lower extremity ulcerations: A differential diagnosis

Vascular Medicine

Volumn 13, Issue 1, 2008, Pages 47-54

  Dean, Steven M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Atypical; Extremity; Ischemic; Ulcerations

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; COLCHICINE; CORTICOSTEROID; CYTOTOXIC AGENT; DAPSONE; FONDAPARINUX; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; THROMBIN INHIBITOR; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; CALCINOSIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; HEPARIN SKIN NECROSIS; HUMAN; LABORATORY TEST; LEG ISCHEMIA; LEG ULCER; PERIPHERAL VASCULAR DISEASE; POLYARTERITIS NODOSA; PRIORITY JOURNAL; REVIEW; SKIN BIOPSY; SKIN DISEASE; SKIN GRAFT; SKIN NECROSIS; SPIDER BITE; VASCULITIS; WARFARIN INDUCED SKIN NECROSIS;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ARACHNIDISM; CALCIPHYLAXIS; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; EMBOLISM, CHOLESTEROL; HEPARIN; HUMANS; ISCHEMIA; LEG ULCER; LOWER EXTREMITY; PERIPHERAL VASCULAR DISEASES; VASCULITIS; WARFARIN;

EID: 42649136525     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X07084729     Document Type: Review

References (38)

1. Second European consensus document on chronic critical leg ischemia. Circulation 1991; 84(4 suppl): IV1-I26.
2. Raines, JK, Darling, RC, Buth, J, et al. Vascular laboratory criteria for the management of peripheral vascular disease of the lower extremities. Surgery 1976; 79: 21-29.
3. Carter, SA, Tate, RB. Value of toe pulse waves in addition to systolic pressure in the assessment of the severity of peripheral arterial disease and critical limb ischemia. J Vasc Surg 1996; 24: 258-265.
4. Diogenes, MJ, Diogenes, PC, Carneiro, RM, et al. Cutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol 2004; 43: 632-637.
5. Alegre, VA, Gastineau, DA, Winkelmann, RK. Skin lesions associated with circulating lupus anticoagulant. Br J Dermatol 1989; 120: 419-429.
6. DiFrancesco, LM, Burkart, P, Hoehn, JG. A cutaneous manifestation of the antiphospholipid antibody syndrome. Ann Plast Surg 2003; 51: 517-521.
7. Creamer, D, Hunt, B, Black, M. Widespread cutaneous necrosis occurring in association with the antiphospholipid syndrome: a report of two cases. Br J Dermatol 2000; 142: 1199-1203.
8. Wilson, WA, Gharavi, AE, Koike, T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid antibody syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
9. Budisavlijevic, MN, Cheek, D, Ploth, DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol 1996; 7: 978-982.
10. Kant, KS, Glueck, HI, Coots, MC, et al. Protein S deficiency and skin necrosis associated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1992; 19: 264-271.
11. Mehta, RL, Scott, G, Sloand, JA, Francis, CW. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med 1990; 88: 252-257.
12. Goli, AK, Goli, SA, Shah, LS, et al. Calciphylaxis: a rare association with alcoholic cirrhosis - are deficiencies in protein C and S the cause? South Med J 2005; 98: 736-739.
13. Fine, A, Zacharias, J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002; 61: 2210-2217.
14. Chertow, GM, Raggi, P, McCarthy, JT, et al. The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003; 23: 307-314.
15. Dean, SM, Werman, H. Calciphylaxis: a favorable outcome with hyperbaric oxygen. Vasc Med 1998; 3: 115-120.
16. Podymow, T, Wherrett, C, Burns, KD. Hyperbaric oxygen in the treatment of calciphylaxis case series. Nephrol Dial Transplant 2001; 16: 2176-2180.
17. Sewell, LD, Weenig, RH, Davis, MD, et al. Low-dose tissue plasminogen activator for calciphylaxis. Arch Dermatol 2004; 140: 1045-1048.
18. Cicone, JS, Petronis, JB, Embert, CD, Spector, DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43: 1104-1108.
19. Monney, P, Nguyen, Q-V, Perroud, H, Descombes, E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 2004; 19: 2130-2132.
20. Eby, CS. Warfarin-induced skin necrosis. Hematol Oncol Clin North Am 1993; 7: 1291-1300.
21. Sallah, S, Abdallah, JM, Gagnon, GA. Recurrent warfarin-induced skin necrosis in kindreds with protein S deficiency. Haemostasis 1998; 28: 25-30.
22. Srinivasan, AF, Rice, L, Bartholomew, JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced tbrombocytopenia. Arch Intern Med 2004; 164: 66-70.
23. Zauber, NP, Stark, MW. Successful warfarin anticoagulant despite protein C deficiency and a history of warfarin necrosis. Ann Intern Med 1986; 104: 659-660.
24. Handschin, AE, Trentz, O, Kock, HJ, Wanner, GA. Low molecular weight heparin-induced skin necrosis - a systematic review. Langenbecks Arch Surg 2005; 390: 249-254.
25. Denton, MD, Mauiyyedi, S, Bazari, H. Heparin-induced skin necrosis in a patient with end-stage renal failure and functional protein S deficiency. Am J Nephrol 2001; 21: 289-293.
26. Ruiz Villaverde, R, Blasco Melguizo, J, Martin Sanchez, MC, et al. Annular leucocytoclastic vasculitis: response to dapsone. J Eur Acad Dermatol Venereol 2002; 16: 544-546.
27. Seybold, H, Simon, M, Schuler, G, et al. Refractory cutaneous necrotizing vasculitis: successful sulfone therapy. Hautzarzt 2006; 57: 47-50.
28. Cabili, S, Teachman, I, Goor, Y. Reversal of gangrenous lesions in the blue toe syndrome with lovastatin - a case report. Angiology 1993; 44: 821-825.
29. Matsumura, T, Matsumoto, A, Ohno, M, et al. A case of cholesterol embolism confirmed by skin biopsy and successfully treated with statins and steroids. Am J Med Sci 2006; 331: 280-283.
30. Radauceanu, A, Avignon, A, Ribstein, I, Monnier, L. Use of a prostacyclin analogue in cholesterol crystal embolism. Diabet Med 1998; 15: 262-263.
31. Elinav, E, Chajek-Shaul, T, Stern, M. Improvement in cholesterol emboli syndrome after iloprost therapy. BMJ 2002; 324: 268-269.
32. Motegi, S, Abe, M, Shimizu, A, et al. Cholesterol crystal embolization: skin manifestation, gastrointestinal and central nervous symptom treated with corticosteroid. J Dermatol 2005; 32: 295-298.
33. Stabellini, N, Cerretani, D, Russo, G, et al. [Renal atheroembolic disease: evaluation of the efficacy of corticosteroid therapy]. G Ital Nefrol 2002; 19: 18-21.
34. Funabiki, K, Masuoka, H, Shimizu, H, et al. Cholesterol crystal embolization [CCE] after cardiac catheterization. Jpn Heart J 2003; 44: 767-774.
35. Isbister, GK, White, J, Currie, BJ, et al. Spider bites: addressing mythology and poor evidence. Am J Trop Med Hyg 2005; 72: 361-367.
36. Dyachenko, P, Ziv, M, Rozenman, D. Epidemiological and clinical manifestations of patients hospitalized with brown recluse spider bite. J Eur Acad Dermatol Venereol 2006; 20: 1121-1125.
37. Diaz, JH. The global epidemiology, syndromic classification, management, and prevention of spider bites. Am J Trop Med Hyg 2004; 71: 239-250.
38. 31P nuclear magnetic resonance spectroscopy. Am J Trop Med Hyg 1997; 56: 335-338.